Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

ABSTRACT: This research study is done to test how well different types of cancer respond to the drug called larotrectinib. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3). Larotrectinib is a drug that blocks the actions of these NTRK genes in cancer cells and can therefore be used to treat cancer.

DISEASE(S): Solid Tumor,Sarcoma,Thyroid Cancer,Melanoma,Colorectal Cancer,Non-small Cell Lung Cancer,Neoplasm Of Unspecified Behavior Of Breast,Breast Cancer,Solid Tumors Harboring Ntrk Fusion,Solid Tumors

PROVIDER: 2200151 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Anti-cancer drug sensitive DNA methylation marker research

Project description:Genome wide DNA methylation profiling of normal and colon cancer and assosiation study between anti-cancer drug respond group and non-respond group. The Illumina Infinium 27k Human DNA methylation Beadchip v1.2 was used to obtain DNA methylation profiles across approximately 27,000 CpGs in 118 paired anti-cancer drug response tested colon cancer and adjacent normal tissues Bisulphite converted DNA from the 248 samples were hybridised to the Illumina Infinium 27k Human Methylation Beadchip v1.2

2011-12-31 | E-GEOD-27130 | biostudies-arrayexpress

Anti-cancer drug sensitive DNA methylation marker research

2011-12-31 | GSE27130 | GEO

DECIPHERING THE SIGNALING NETWORK LANDSCAPE OF BREAST CANCER IMPROVES DRUG SENSITIVITY PREDICTION

Project description:Although genetic and epigenetic abnormalities in breast cancer have been extensively studied, it remains difficult to identify those patients who will respond to particular therapies. This is due in part to our lack of understanding of how the variability of cellular signaling affects drug sensitivity. Here, we used mass cytometry to characterize the single-cell signaling landscapes of 62 breast cancer cell lines and five lines from healthy tissue. We quantified 34 markers in each cell line upon stimulation by the growth factor EGF in the presence or absence of five kinase inhibitors. These data – on more than 80 million single cells from 4,000 conditions – were used to fit mechanistic signaling network models that provide unprecedented insights into the biological principles of how cancer cells process information. Our dynamic single-cell-based models more accurately predicted drug sensitivity than static bulk measurements for drugs targeting the PI3K-MTOR signaling pathway. Finally, we identified genomic features associated with drug sensitivity by using signaling phenotypes as proxies, including a missense mutation in DDIT3 predictive of PI3K-inhibition sensitivity. This provides proof of principle that single-cell measurements and modeling could inform matching of patients with appropriate treatments in the future.

2021-04-20 | PXD017199 | Pride

Functional drug testing of pediatric acute lymphocytic leukemia cells by single-cell transcriptome sequencing for mapping cellular drug response

Project description:Functional precision medicine (FPM) aims to match the right patients to the right drugs by using specific features of the individual’s cancer cells. Recently, FPM has been propelled by technologies that enable high throughput ex vivo drug profiling to tailor treatments for individual patients. Here, we present a proof of concept study for an integrated experimental system that incorporates ex vivo treatment response with a single-cell gene expression output that enables barcoding of several drug conditions in one single-cell sequencing experiment. We perform functional annotation of drug resistance using the glucocorticoid-resistant E/R+ REH cells as a cellular model and evaluate three different approaches for single-cell transcriptome sequencing (scRNA-seq). Using this integrated system, we show that all scRNA-seq methods accurately reflected gene expression changes in the system, with high cell recovery and accurate tagging of the different drug conditions. Furthermore, we identified a substantial single-cell transcriptional response to fludarabine, a drug of particular interest for treatment of high-risk ALL.

2024-01-04 | GSE229617 | GEO

Metabolic state determines drug response in liver cancer

Project description:Drug resistance is one of the most challenging problems in liver cancer research. The hepatocellular carcinoma cell line HLE is highly dependent on exogenous glutamine for proliferation. In this cell line, we have found that glutamine deprivation leads to proliferation arrest, phosphorylation of extracellular signal-regulated kinase (ERK), and metabolic alterations at gene, protein, metabolite levels. Interestingly, while HLE cells respond to kinase inhibitors in their unperturbed metabolic state, they display pro-tumourigenic phenotypes such as increased aerobic glycolysis and proliferation when treated with inhibitors of MAPK/ERK pathway in the impaired metabolic state induced by glutamine deprivation. Thus, the aim of this microarray analysis is to determine the genomic alterations that accompany glutamine deprivation and treatment with pERK inhibitor U0126. The anticipated alterations could shed light on novel molecular mechanisms underlying drug resistance, and may be useful for predicting therapeutic response in liver cancer.

2018-11-29 | GSE123062 | GEO

Expression data from children and adolescents treated with Fluoxetine

Project description:It is well-known that between 40 and 50% of patients taking antidepressants do not respond to treatment or relapse. Genome wide gene expression studies can help us to understand better the response to antidepressants, revealing the effects of both genetic background and environmental/epigenetic factors. We used microarrays to detail the response to Fluoxetine in children and adolescents, analysing the expression just before intake of drug and 8 weeks after starting the treatment.

2019-12-31 | GSE128387 | GEO

Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance

Project description:Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance

| PRJNA382641 | ENA

Transcription profiling of human breast cancer cell lines (23)

Project description:Transcriptional profiling was conducted on RNA from 23 breast cancer cell lines to identify genes whose expression level correlates with sensitivity of particular drug Experiment Overall Design: Baseline gene expression profiling was performed using 23 breast cancer cell lines to identify genomic signatures highly correlated with in vitro sensitivity to a particular drug

2008-06-15 | E-GEOD-6569 | biostudies-arrayexpress

Understanding COVID-19 in children and adults

Project description:Purpose: This study aims to characterize the early innate and adaptive responses induced by SARS-CoV-2 infection in children and adults over time up to 8 weeks post symptoms onset (POS). We report the gene signature of COVID-19 over the course of the disease in both age groups. The kinetic of infection was divided in 5-time intervals according to the calculated days POS: interval 1 (0-5), interval 2 (6-14), interval 3 (15-22), interval 4 (23-35), and interval 5 (36-81). Methods: RNA extraction was performed automatically via the PAXgene Blood miRNA Kit and the QIAcube instrument (Qiagen) following the manufacturer’s protocol. RNA concentration and quality were assessed by using the Qubit instrument (Invitrogen) and the Agilent 2100 Bioanalyzer, respectively. The Stranded Total RNA Ribo-Zero Plus kit from Illumina was used for the library preparation with 100 ng of total RNA as input. Library molarity and quality were assessed with the Qubit and Tapestation using a DNA High sensitivity chip (Agilent Technologies). Libraries were pooled at 2 nM for clustering and sequenced on an Illumina HiSeq 4000 sequencer for a minimum of 30 million single-end 100 reads per sample. Main results: (I) we observed an antiviral-IFN-signature and innate-cell-activation within the first 5 days post symptoms onset (POS), while genes associated with CD4 T-cell responses, plasma cells and immunoglobulin were upregulated in both age groups during the first two weeks POS, indicative of SARS-CoV-2-specific adaptive immune responses; (II) in adults, genes associated with IFN antiviral responses and activated dendritic cells were maintained during the second week of disease, and subsided only after 14 days. By contrast, those transcriptome changes subsided already after 5 days in children.

2021-09-22 | GSE166190 | GEO

Identification of drug associated genes in ovarian cancer by RNA profiling

Project description:Two expression profilings were conducted in order to identify drug-associated genes in ovarian cancers. The first expression profiling was performed between RNAs from chemosensitive ovarian cancers and chemoresistant ovarian cancers. The second analysis was using a drug sensitive ovarian cancer cell line and a multi-drug resistant ovarian cancer cell line.

2010-06-30 | E-GEOD-2058 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data